The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

ABSTRACT:

Background

Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used.

Objective

To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States.

Design

Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses.

Data sources

Randomized trials, observational cohorts, and national health care spending surveys.

Target population

8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic).

Time horizon

Lifetime.

Perspective

Paye

SUBMITTER: Linas BP 

PROVIDER: S-EPMC4420667 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature